Wednesday, November 25, 2009, 10:19am SGT - The Singapore stock market closes in 6 hours and 41 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Aastrom Biosciences, Inc. (ASTM)

At 4:59AM SGT: 0.2933 USD  Down 0.0147 (4.77%)  
 MORE ON ASTM 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Aastrom Biosciences, Inc. (NCM:ASTM) Delayed quote dataEdit
Last Trade:0.2933 USD
Trade Time:4:59AM SGT
Change:Down 0.0147 (4.77%)
Prev Close:0.308
Open:0.295
Bid:N/A
Ask:0.305 x 4000
1y Target Est:0.50
Day's Range:0.29 - 0.3079
52wk Range:0.29 - 0.78
Volume:892,091
Avg Vol (3m):1,627,860
Market Cap:51.03M
P/E (ttm):N/A
EPS (ttm):-0.105
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add ASTM to Portfolio   Download Data

 HEADLINES 
•Updates and Results From Aastrom's Vascular Program Presented at an American Heart Association Satellite Symposium
GlobeNewswire (Mon, Nov 16)
•Interim Results From Aastrom's IMPACT-DCM Cardiac Trial Presented at The American Heart Association Meeting
GlobeNewswire (Mon, Nov 16)
•AASTROM BIOSCIENCES INC Financials
EDGAR Online Financials (Fri, Nov 13)
•Trading Outlook for Hard To Treat Diseases Inc. Issued by InvestorSoup.com
GlobeNewswire (Fri, Nov 13)
•Can Stem Cells Put an End To Paralysis?
Indie Research (Thu, Nov 12)
•Aastrom to Initiate Second Phase II Clinical Trial for Treatment of Severe Chronic Heart Failure
GlobeNewswire (Wed, Nov 11)
•Morningstar Strategist Says Healthcare Bill Will Be Law By End Of Year: Is Your Portfolio Ready?
Wall Street Transcript (Tue, Nov 10)
•AASTROM BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Sat, Nov 7)
•Aastrom Biosciences Reports First Quarter Fiscal Year 2010 Financial Results
GlobeNewswire (Sat, Nov 7)
•Stem Cell Traders Flock to Geron
Indie Research (Fri, Oct 30)
More Headlines for ASTM...
 ANALYST 
EPS Est (next year) (Jun-10) :N/A
EPS Est (in 2 years) (Jun-11) :N/A
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Aastrom Biosciences, Inc. engages in developing autologous cell products for the repair or regeneration of human tissue. Its proprietary tissue repair cell (TRC) technology involves the use of a patient's own cells to manufacture products to ...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices